15-Jul-2026
No headlines found.
Cytek Biosciences Opens New Innovation Center in Bellevue to Advance R&D and Customer Engagement
Globe Newswire (Wed, 15-Jul 5:00 PM ET)
Cytek Biosciences to participate at the Singular Research's Las Vegas Invitational Conference
Globe Newswire (Wed, 10-Jun 4:05 PM ET)
Marvell Technology and Flex Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
PRNewswire (Fri, 5-Jun 7:26 PM ET)
Cytek Biosciences to Unveil Next-Generation Spectral Flow Cytometry Innovations at CYTO 2026
Globe Newswire (Tue, 2-Jun 5:07 PM ET)
Globe Newswire (Wed, 13-May 9:00 AM ET)
Cytek Biosciences Reports First Quarter 2026 Financial Results
Globe Newswire (Thu, 7-May 4:05 PM ET)
Cytek Biosciences to Report First Quarter 2026 Financial Results on May 7, 2026
Globe Newswire (Thu, 23-Apr 4:05 PM ET)
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of research and clinical tools with its novel technical approach of leveraging the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its patented FSP technology optimizes sensitivity and accuracy through its optical and electronic designs that utilize an inventive method of light detection and distribution to a specifically selected number and type of detectors. Its FSP cell analyzers, the Cytek Aurora, Northern Lights, and Cytek Aurora Evo systems, deliver high-resolution, high-content and high-sensitivity cell analysis and address the inherent limitations of other technologies.
Cytek Biosciences trades on the NASDAQ stock market under the symbol CTKB.
As of July 15, 2026, CTKB stock price climbed to $4.65 with 535,660 million shares trading.
CTKB has a beta of 0.46, meaning it tends to be less sensitive to market movements. CTKB has a correlation of 0.01 to the broad based SPY ETF.
CTKB has a market cap of $600.51 million. This is considered a Small Cap stock.
Last quarter Cytek Biosciences reported $44 million in Revenue and -$.15 earnings per share. This fell short of revenue expectation by $-44 million and missed earnings estimates by -$.06.
In the last 3 years, CTKB traded as high as $9.87 and as low as $2.37.
The top ETF exchange traded funds that CTKB belongs to (by Net Assets): IWM, VTI, VXF, IWN, IBB.
CTKB has outperformed the market in the last year with a price return of +38.8% while the SPY ETF gained +22.0%. However, in the short term, CTKB had mixed performance relative to the market. It has underperformed in the last 3 months, returning +0.6% vs +9.0% return in SPY. But in the last 2 weeks, CTKB shares have fared better than the market returning +5.0% compared to SPY +1.1%.
CTKB support price is $4.46 and resistance is $4.78 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTKB shares will trade within this expected range on the day.